Drew Ranieri
Stock Analyst at Morgan Stanley
(1.25)
# 3,619
Out of 5,182 analysts
170
Total ratings
45.65%
Success rate
-11.58%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $12.36 | +86.08% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $90.74 | +10.20% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $9.35 | +124.60% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.40 | +150.00% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $321.43 | +38.44% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $10.74 | +151.40% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $1.91 | +318.85% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $16.21 | +35.72% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $16.89 | -52.63% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $4.32 | +1,809.72% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $26.49 | +43.45% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $59.84 | +60.43% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $24.63 | +5.56% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $149.52 | +97.30% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $135.52 | +106.61% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $9.95 | -49.75% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $17.94 | +290.19% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $466.64 | -35.71% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $12.36
Upside: +86.08%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $90.74
Upside: +10.20%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $9.35
Upside: +124.60%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.40
Upside: +150.00%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $321.43
Upside: +38.44%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $10.74
Upside: +151.40%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $1.91
Upside: +318.85%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $16.21
Upside: +35.72%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $16.89
Upside: -52.63%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $4.32
Upside: +1,809.72%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $26.49
Upside: +43.45%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $59.84
Upside: +60.43%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $24.63
Upside: +5.56%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $149.52
Upside: +97.30%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $135.52
Upside: +106.61%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $9.95
Upside: -49.75%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $17.94
Upside: +290.19%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $466.64
Upside: -35.71%